Viral delivery for gene therapy against cell movement in cancer

Advanced Drug Delivery Reviews

Volumn 63, Issue 8, 2011, Pages 671-677

  Wu, Te Lang ^a,b   Zhou, Dongming ^a,c  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Cancer gene therapy; Cell movement; Epithelial to mesenchymal transition; Metastasis; Oncolytic viral vector

Indexed keywords

CANCER GENE THERAPY; CELL MOVEMENT; EPITHELIAL-TO-MESENCHYMAL TRANSITION; METASTASIS; VIRAL VECTORS;

CELLS; CHEMOTHERAPY; DISEASES; GENETIC ENGINEERING; TUMORS; VECTORS; VIRUSES;

GENE THERAPY;

FLUOROURACIL; GANCICLOVIR; INTERLEUKIN 12; MICRORNA; MICRORNA 10B; MICRORNA 141; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 34A; MICRORNA 429; ONCOLYTIC VIRUS; ONYX 015; SITIMAGENE CERADENOVEC; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VECTOR;

CANCER GENE THERAPY; CANCER SURVIVAL; CELL MOTION; COLORECTAL CARCINOMA; CYTOPATHOGENIC EFFECT; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSARCOMA; GASTROINTESTINAL CARCINOMA; HUMAN; IMMUNE RESPONSE; LIVER CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS POTENTIAL; MOUTH CARCINOMA; NATURAL KILLER CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLASMAPHERESIS; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REOVIRUS; REVIEW; SEROTYPE; SUICIDE GENE THERAPY; TUMOR CELL DESTRUCTION; TUMOR GROWTH; UNTRANSLATED REGION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION; VIRUS VIRULENCE;

ANIMALS; CELL MOVEMENT; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIRUSES; VIRUS REPLICATION; VIRUSES;

EID: 79959957518     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.005     Document Type: Review

References (104)

1. Walther W., Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000, 60:249-271.
2. Sheridan C. Gene therapy finds its niche. Nat. Biotechnol. 2011, 29:121-128.
3. Wu T.L., Ertl H.C. Immune barriers to successful gene therapy. Trends Mol. Med. 2009, 15:32-39.
4. Krasinskas A.M. EGFR Signaling in Colorectal Carcinoma. Patholog. Res. Int. 2011, 2011:932932.
5. Lockhart A.C., Berlin J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005, 32:52-60.
6. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann. Oncol. 2010, 21:vii89-vii92.
7. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
8. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol. Ther. 2009, 17:1333-1339.
9. Biederer C., Ries S., Brandts C.H., McCormick F. Replication-selective viruses for cancer therapy. J. Mol. Med. 2002, 80:163-175.
10. Jiang H., Gomez-Manzano C., Alemany R., Medrano D., Alonso M., Bekele B.N., Lin E., Conrad C.C., Yung W.K., Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55kDa or E1B-55kDa deletions in malignant gliomas. Neoplasia 2005, 7:48-56.
11. Kamizono J., Nagano S., Murofushi Y., Komiya S., Fujiwara H., Matsuishi T., Kosai K. Survivin responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer. Res. 2005, 65:5284-5291.
12. Wirth T., Zender L., Schulte B., Mundt B., Plentz R., Rudolph K.L., Manns M., Kubicka S., Kühnel F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003, 63:3181-3188.
13. Pfitzenmaier J., Ellis W.J., Arfman E.W., Hawley S., McLaughlin P.O., Lange P.H., Vessella R.L. Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006, 97:1309-1313.
14. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
15. Lanson N.A., Friedlander P.L., Schwarzenberger P., Kolls J.K., Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor selective tumor lysis. Cancer Res. 2003, 63:7936-7941.
16. Zheng F.Q., Xu Y., Yang R.J., Wu B., Tan X.H., Qin Y.D., Zhang Q.W. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta. Pharmacol. Sin. 2009, 30:617-627.
17. Habib N.A., Sarraf C.E., Mitry R.R., Havlík R., Nicholls J., Kelly M., Vernon C.C., Gueret-Wardle D., El-Masry R., Salama H., Ahmed R., Michail N., Edward E., Jensen S.L. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 2001, 12:219-222.
18. Morley S., MacDonald G., Kirn D., Kaye S., Brown R., Soutar D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin. Cancer Res. 2004, 10:4357-4362.
19. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., Randlev B., Heise C., Uprichard M., Hatfield M., Rome L., Rubin J., Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus(dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002, 62:6070-6079.
20. Tatsis N., Blejer A., Lasaro M.O., Hensley S.E., Cun A., Tesema, Li Y., Gao G.P., Xiang Z.Q., Zhou D., Wilson J.M., Ertl H.C. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol. Ther. 2007, 15:608-617.
21. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., Giles-Davis W., Wilson J.M., Ertl H.C. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 2003, 170:1416-1422.
22. Roy S., Gao G., Lu Y., Zhou X., Lock M., Calcedo R., Wilson J.M. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther. 2004, 15:519-530.
23. Chen H., Xiang Z.Q., Li Y., Kurupati R.K., Jia B., Zhou D.M., Hutnick N., Yuan S., Gray C., Serwanga J., Auma B., Kaleebu P., Zhou X., Betts M.R., Ertl H.C. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 2010, 84:10522-10532.
24. Zhou D., Zhou X., Bian A., Li H., Chen H., Small J.C., Li Y., Giles-Davis W., Xiang Z., Ertl H.C. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat. Protoc. 2010, 5:1775-1785.
25. Heldwein E.E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol. Life Sci. 2008, 65:1653-1668.
26. Jones C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin. Microbiol. Rev. 2003, 16:79-95.
27. Halford W.P., Kemp C.D., Isler J.A., Davido D.J., Schaffer P.A. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J. Virol. 2001, 75:6143-6153.
28. Meignier B., Longnecker R., Mavromara-Nazos P., Sears A.E., Roizman B. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 1988, 162:251-254.
29. Leopardi R., Van Sant C., Roizman B. The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc. Natl. Acad. Sci. USA 1997, 94:7891-7896.
30. Benetti L., Roizman B. Herpes simplex virus protein kinase US3 activates and functionally overlaps protein kinase A to block apoptosis. Proc. Natl. Acad. Sci. USA 2004, 101:9411-9416.
31. Whitley R.J., Kern E.R., Chatterjee S., Chou J., Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 1993, 91:2837-2843.
32. Kasuya H., Pawlik T.M., Mullen J.T., Donahue J.M., Nakamura H., Chandrasekhar S., Kawasaki H., Choi E., Tanabe K.K. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 2004, 64:2561-2567.
33. McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C., McNab D., Perry L.J., Scott J.E., Taylor P. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol. 1988, 69:1531-1574.
34. Zhe R., Mei-Ying Z., Kitazato K., Kobayash N., Qin-Chang Z., Pei-Zhuo Z., Zhi-Rong Y., Yi-Fei W. Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA. Arch. Virol. 2008, 153:1401-1406.
35. Jacobson J.G., Leib D.A., Goldstein D.J., Bogard C.L., Schaffer P.A., Weller S.K., Coen D.M. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989, 173:276-283.
36. Goldstein D.J., Weller S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 1988, 62:196-205.
37. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995, 1:938-943.
38. Toda M., Rabkin S.D., Martuza R.L. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene. Ther. 1998, 2177-2185.
39. Nakano K., Todo T., Chijiiwa K., Tanaka M. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther. 2001, 3:431-437.
40. Samoto K., Ehtesham M., Perng G.C., Hashizume K., Wechsler S.L., Nesburn A.B., Black K.L., Yu J.S. A herpes simplex virus type 1 mutant with gamma 34.5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery 2002, 50:599-605.
41. Lacunza E., Baudis M., Colussi A.G., Segal-Eiras A., Croce M.V., Abba M.C. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet. Cytogenet. 2010, 201:102-110.
42. Chauhan S.C., Singh A.P., Ruiz F., Johansson S.L., Jain M., Smith L.M., Moniaux N., Batra S.K. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod. Pathol. 2006, 19:1386-1394.
43. Adsay N.V., Basturk O., Cheng J.D., Andea A.A. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin. Radiat. Oncol. 2005, 15:254-264.
44. Wong R.J., Patel S.G., Kim S., DeMatteo R.P., Malhotra S., Bennett J.J., St-Louis M., Shah J.P., Johnson P.A., Fong Y. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. 2001, 12:253-265.
45. Derubertis B.G., Stiles B.M., Bhargava A., Gusani N.J., Hezel M., D'Angelica M., Fong Y. Cytokine secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer. Gene Ther. 2007, 14:590-597.
46. Wong R.J., Chan M.K., Yu Z., Kim T.H., Bhargava A., Stiles B.M., Horsburgh B.C., Shah J.P., Ghossein R.A., Singh B., Fong Y. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 2004, 10:251-259.
47. Jarnagin W.R., Zager J.S., Klimstra D., Delman K.A., Malhotra S., Ebright M., Little S., DeRubertis B., Stanziale S.F., Hezel M., Federoff H., Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther. 2003, 10:215-223.
48. Wong R.J., Chan M.K., Yu Z., Ghossein R.A., Ngai I., Adusumilli P.S., Stiles B.M., Shah J.P., Singh B., Fong Y. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res. 2004, 10:4509-4516.
49. Geevarghese S.K., Geller D.A., de Haan H.A., Hörer M., Knoll A.E., Mescheder A., Nemunaitis J., Reid T.R., Sze D.Y., Tanabe K.K., Tawfik H. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum. Gene. Ther. 2010, 21:1119-1128.
50. Markert J.M., Medlock M.D., Rabkin S.D., Gillespie G.Y., Todo T., Hunter W.D., Palmer C.A., Feigenbaum F., Tornatore C., Tufaro F., Martuza R.L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7:867-874.
51. Fong Y., Kim T., Bhargava A., Schwartz L., Brown K., Brody L., Covey A., Karrasch M., Getrajdman G., Mescheder A., Jarnagin W., Kemeny N. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol. Ther. 2009, 17:389-394.
52. Hu J.C., Coffin R.S., Davis C.J., Graham N.J., Groves N., Guest P.J., Harrington K.J., James N.D., Love C.A., McNeish I., Medley L.C., Michael A., Nutting C.M., Pandha H.S., Shorrock C.A., Simpson J., Steiner J., Steven N.M., Wright D., Coombes R.C. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony stimulating factor. Clin. Cancer Res. 2006, 12:6737-6747.
53. Senzer N.N., Kaufman H.L., Amatruda T., Nemunaitis M., Reid T., Daniels G., Gonzalez R., Glaspy J., Whitman E., Harrington K., Goldsweig H., Marshall T., Love C., Coffin R., Nemunaitis J.J. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 2009, 27:5763-5771.
54. Sobol P.T., Boudreau J.E., Stephenson K., Wan Y., Lichty B.D., Mossman K.L. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol. Ther. 2011, 19:335-344.
55. Ober B.T., Brühl P., Schmidt M., Wieser V., Gritschenberger W., Coulibaly S., Savidis-Dacho H., Gerencer M., Falkner F.G. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J. Virol. 2002, 76:7713-7723.
56. Grandpre L.E., Duke-Cohan J.S., Ewald B.A., Devoy C., Barouch D.H., Letvin N.L., Reinherz E.L., Baden L.R., Dolin R., Seaman M.S. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine 2009, 27:1549-1556.
57. McFadden G. Poxvirus tropism. Nat. Rev. Microbiol. 2005, 3:201-213.
58. Lalani A.S., Masters J., Zeng W., Barrett J., Pannu R., Everett H., Arendt C.W., McFadden G. Use of chemokine receptors by poxviruses. Science 1999, 286:1968-1971.
59. Buller R.M., Chakrabarti S., Cooper J.A., Twardzik D.R., Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. 1988, 62:866-874.
60. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 2009, 9:64-71.
61. Thorne S.H., Hwang T.H., O'Gorman W.E., Bartlett D.L., Sei S., Kanji F., Brown C., Werier J., Cho J.H., Lee D.E., Wang Y., Bell J., Kirn D.H. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 2007, 117:3350-3358.
62. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72:1031-1038.
63. Park B.H., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., Oh S.Y., Han S.Y., Yoon J.H., Hong S.H., Moon A., Speth K., Park C., Ahn Y.J., Daneshmand M., Rhee B.G., Pinedo H.M., Bell J.C., Kirn D.H. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008, 9:533-542.
64. Amato R.J., Shingler W., Goonewardena M., de Belin J., Naylor S., Jac J., Willis J., Saxena S., Hernandez-McClain J., Harrop R. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J. Immunother. 2009, 32:765-772.
65. Amato R.J., Hawkins R.E., Kaufman H.L., Thompson J.A., Tomczak P., Szczylik C., McDonald M., Eastty S., Shingler W.H., de Belin J., Goonewardena M., Naylor S., Harrop R. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 2010, 16:5539-5547.
66. Comins C., Heinemann L., Harrington K., Melcher A., De Bono J., Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin. Oncol. (R Coll Radiol). 2008, 20:548-554.
67. Fiola C., Peeters B., Fournier P., Arnold A., Bucur M., Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer. 2006, 119:328-338.
68. Barton E.S., Forrest J.C., Connolly J.L., Chappell J.D., Liu Y., Schnell F.J., Nusrat A., Parkos C.A., Dermody T.S. Junction adhesion molecule is a receptor for reovirus. Cell 2001, 104:441-451.
69. Tyler K.L., Clarke P., DeBiasi R.L., Kominsky D., Poggioli G.J. Reoviruses and the host cell. Trends. Microbiol. 2001, 9:560-564.
70. Ferreira L., Villar E., Muñoz-Barroso I. Gangliosides and N-glycoproteins function as Newcastle disease virus receptors. Int. J. Biochem. Cell. Biol. 2004, 36:2344-2356.
71. Villar E., Barroso I.M. Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj. J. 2006, 23:5-17.
72. Krishnamurthy S., Takimoto T., Scroggs R.A., Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 2006, 80:5145-5155.
73. Laurie S.A., Bell J.C., Atkins H.L., Roach J., Bamat M.K., O'Neil J.D., Roberts M.S., Groene W.S., Lorence R.M. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006, 12:2555-2562.
74. Liu T.C., Kirn D. Systemic efficacy with oncolytic virus therapeutics: Clinic proof-of-concept and future directions. Cancer Res. 2007, 67:429-432.
75. Elankumaran S., Chavan V., Qiao D., Shobana R., Moorkanat G., Biswas M., Samal S.K. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J. Virol. 2010, 84:3835-3844.
76. Vigil A., Park M.S., Martinez O., Chua M.A., Xiao S., Cros J.F., Martínez-Sobrido L., Woo SL S.L., García-Sastre A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007, 67:8285-8292.
77. Haviv Y.S., Blackwell J.L., Kanerva A., Nagi P., Krasnykh V., Dmitriev I., Wang M., Naito S., Lei X., Hemminki A., Carey D., Curiel D.T. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 2002, 62:4273-4281.
78. Bauerschmitz G.L., Lam J.T., Kanerva A., Suzuki K., Dmitriev I., Krasnykh V., Mikheeva G.V., Barnes M.N., Alvarez R.D., Dall P., Alemany R., Curiel D.T., Hemminki A. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 2002, 62:1266-1270.
79. Wakayama M., Abei M., Kawashima R., Seo E., Fukuda K., Ugai H., Murata T., Tanaka N., Hyodo I., Hamada H., Yokoyama K.K. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin. Cancer Res. 2007, 13:3043-3050.
80. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 2010, 18:243-250.
81. Takayama K., Reynolds P.N., Short J.J., Kawakami Y., Adachi Y., Glasgow J.N., Rots M.G., Krasnykh V., Douglas J.T., Curiel D.T. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 2003, 309:282-293.
82. Eriksson M., Guse K., Bauerschmitz G., Virkkunen P., Tarkkanen M., Tanner M., Hakkarainen T., Kanerva A., Desmond R.A., Pesonen S., Hemminki A. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol. Ther. 2007, 15:2088-2093.
83. Tanaka T., Huang J., Hirai S., Kuroki M., Kuroki M., Watanabe N., Tomihara K., Kato K., Hamada H. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin. Cancer Res. 2006, 12:3803-3813.
84. Parrott M.B., Adams K.E., Mercier G.T., Mok H., Campos S.K., Barry M.A. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol. Ther. 2003, 8:688-700.
85. Kent O.A., Mendell J.T. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196.
86. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev. 2009, 28:369-378.
87. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
88. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
89. Robson E.J., Khaled W.T., Abell K., Watson C.J. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 2006, 74:254-264.
90. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
91. Zhou C., Nitschke A.M., Xiong W., Zhang Q., Tang Y., Bloch M., Elliott S., Zhu Y., Bazzone L., Yu D., Weldon C.B., Schiff R., McLachlan J.A., Beckman B.S., Wiese T.E., Nephew K.P., Shan B., Burow M.E., Wang G. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res. 2008, 10:R105.
92. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
93. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009, 15:5060-5072.
94. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., Teruya-Feldstein J., Bell G.W., Weinberg R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28:341-347.
95. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
96. Edge R.E., Falls T.J., Brown C.W., Lichty B.D., Atkins H., Bell J.C. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther. 2008, 16:1437-1443.
97. Ahmed A., Thompson J., Emiliusen L., Murphy S., Beauchamp R.D., Suzuki K., Alemany R., Harrington K., Vile R.G. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol. 2003, 21:771-777.
98. Chen Y., DeWeese T., Dilley J., Zhang Y., Li Y., Ramesh N., Lee J., Pennathur-Das R., Radzyminski J., Wypych J., Brignetti D., Scott S., Stephens J., Karpf D.B., Henderson D.R., Yu D.C. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001, 261:5453-5460.
99. Su C., Peng L., Sham J., Wang X., Zhang Q., Chua D., Liu C., Cui Z., Xue H., Wu H., Yang Q., Zhang B., Liu X., Wu M., Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 2006, 13:918-927.
100. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., McCart J.A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 2010, 18:251-263.
101. Takakura M., Nakamura M., Kyo S., Hashimoto M., Mori N., Ikoma T., Mizumoto Y., Fujiwara T., Urata Y., Inoue M. Intraperitoneal administration of telomerase- specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther. 2010, 17:11-19.
102. Ren X.W., Liang M., Meng X., Ye X., Ma H., Zhao Y., Guo J., Cai N., Chen H.Z., Ye S.L., Hu F. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther. 2006, 13:159-168.
103. Willmon C., Harrington K., Kottke T., Prestwich R., Melcher A., Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 2009, 17:1667-1676.
104. Thorne S.H., Negrin R.S., Contag C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006, 311:1780-1784.